Manejo de la abstinencia aguda de 7-hidroximitraginina tras el uso crónico a altas dosis: un reporte de caso

To report acute opioid withdrawal following abrupt cessation of high-dose 7-hydroxymitragynine (7-OH) in a patient who transitioned from kratom, and to outline pharmacist-focused assessment, management, and regulatory counseling strategies including a formal causality assessment.

A 43-year-old male with opioid use disorder presented with nausea, diarrhea, abdominal cramping, restlessness, chills/clamminess, and anxiety after discontinuing concentrated 7-OH (360 mg/day; last 30 mg dose ∼48 hours prior). Vitals: BP 138/93 mmHg, T 37.7°C, HR 84 bpm, RR 16; pupils 2-3 mm; Clinical Opioid Withdrawal Scale (COWS) 5. He had transitioned from kratom to 7-OH ∼18 months earlier. He met DSM-5 criteria for moderate opiate use disorder, though he never engaged in formal treatment. The patient reported that he transitioned from kratom to concentrated 7-OH products because he perceived stronger, faster opioid-like effects and required smaller quantities to avoid withdrawal. ED management included buprenorphine/naloxone 4/1 mg SL, adjuncts (clonidine, ondansetron, loperamide, methocarbamol, NSAIDs, acetaminophen), counseling on precipitated withdrawal, and referral for treatment. A Naranjo assessment supported probable causality (score = 6).

Concentrated 7-OH products differ from kratom leaf and can produce dependence and withdrawal; pharmacists should screen for these products, time buprenorphine initiation to moderate withdrawal, provide harm-reduction counseling, and incorporate evolving state regulations into patient education.